NASDAQ: PHXM - PHAXIAM Therapeutics S.A.

Yield per half year: 0%
Sector: Healthcare

Share chart PHAXIAM Therapeutics S.A.

Extended chart Simple chart
Financial Markets by TradingView

About

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients.

more details
The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

EBITDA -0.0326
EV/EBITDA -30.25
IPO date 2023-06-29
ISIN US29604W1080
Industry Biotechnology
P/BV 8.68
Sector Health Care
Валюта usd
Валюта отчета eur
Сайт https://www.phaxiam.com
Цена ао 3.1
Change price per day: 0% (3.1)
Change price per week: 0% (3.1)
Change price per month: 0% (3.1)
Change price per 3 month: 0% (3.1)
Change price per half year: 0% (3.1)
Change price per year: -30.18% (4.44)
Change price per 3 year: +40.91% (2.2)
Change price per 5 year: -40.38% (5.2)
Change price per 10 year: 0% (3.1)
Change price per year to date: 0% (3.1)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 972.92 10
Yield Ebitda, % -39.35 0
Yield EPS, % -99.68 0
Total: 2
More



Head Job title Payment Year of birth
Mr. Eric Soyer Ph.D. Deputy CEO, Deputy GM, CFO & COO 418.14k 1966 (59 years)
Dr. Jérôme Bailly Pharm.D. Deputy CEO, Deputy GM, Chief Quality Officer & Qualified Person 272.99k 1979 (46 years)
Mr. Thibaut du Fayet Chief Executive Officer N/A 1968 (57 years)
Ms. Céline Breda Chief Technology Officer N/A 1971 (54 years)
Ms. Cindy Fevre Chief Scientific Officer N/A
Naomi Eichenbaum Director Investor Relations N/A
Ms. Anne-Cécile Fumey Vice President of Human Resources N/A 1976 (49 years)
Ms. Karine Charton Ph.D. Chief Business Officer N/A
Ms. Frederique Vieville Chief Regulatory Officer N/A
Dr. Pascal Birman M.D. Chief Medical Officer

Address: France, Lyon, 60 Avenue Rockefeller - open in Google maps, open in Yandex maps
Website: https://www.phaxiam.com